摘要
目的评价他汀类药物在慢性心力衰竭(chronic heart failure,CHF)治疗中价值。方法从2015年9月,筛选心血管内科收治CHF患者抽签分组,截止2016年7月,对照组、观察组各入组45例,对照组常规治疗,观察组联合他汀类药物,持续16周。结果对照组、观察组各退出2例。治疗后,观察组HR、ET-1、BNP分别为(74.6±11.6)次/min、(30.5±3.6)pg/mL、(170.8±126.6)pg/mL低于对照组(79.6±10.5)次/min、(34.4±4.1)pg/mL、(274.3±108.4)pg/mL,观察组脂联素(32.6±4.5)mmol/L高于对照组(29.5±4.8)mmol/L,治疗后观察组心电图异常率58.14%低于对照组81.40%,差异有统计学意义(P<0.05)。结论即使非高脂血症CHF患者,联合他汀类药物,也可明显获益。
Objective This paper tries to evaluate the value of statins in the treatment of chronic heart failure（CHF）.Methods Patients with CHF admitted in this hospital from September 2015 to July 2016 were selected and divided into the control group and the observation group, with 45 cases each group, the control group received routine treatment, the observation group added statins treatment, and both groups continued for 16 weeks. Results 2 patients in the control group and the observation group were excluded. After treatment, levels of HR, ET-1, BNP in the observation group were（74.6±11.6）times/min,（30.5±3.6） pg/mL,（170.8±126.6） pg/mL, lower than that of the control group of（79.6±10.5）times/min,（34.4±4.1）pg/mL,（274.3±108.4） pg/mL,the level of adiponectin in the observation group was（32.6±4.5） mmol/L,higher than that in the control group of（29.5 ±4.8）mmol/L, the abnormal rate of ECG in the observation group was58.14%, lower than 81.40% in the control group, the difference was statistically significant（P0.05）. Conclusion Statins is even beneficial to the non-hyperlipidemic patients with CHF.
出处
《系统医学》
2017年第12期50-52,共3页
Systems Medicine
